As at 12 June 2023, the number of shares in issue was 59,453,714. The company does not hold any ordinary shares in treasury.
At 12 June 2023, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:
|Shareholder||No. of ordinary shares||% of issued share capital|
|Invest Northern Ireland||3,197,865||5.38|
|Amati Global Investors Limited||2,341,463||3.94|
|Viridian Growth Fund LP||1,831,500||3.08|
|Director||No. of ordinary shares||% of issued share capital|
|Dr Richard John Buick||631,250||1.06|
|Colin James Walsh 1||600,000 2||1.01|
|Sonya Maria Ferguson||502,567||0.85|
|Dr Simon Gordon Douglas||455,800||0.77|
|Dr Adrian Kinkaid||144,000||0.24|
|Hamniv (GP) Limited 3||1,400,000||2.35|
1Colin Walsh is the Chief Executive and founder of Crescent Capital NI Limited ("Crescent Capital"), which is the fund manager for Crescent Capital III LP which holds 613,382 Ordinary Shares.
2 Subscription shares applied for by Walsh Strategic Management Limited, a company controlled by Colin Walsh
3 Hamniv (GP) Limited is a subsidiary of Crescent Capital.
Shares not in public hands
Insofar as it is aware, as at 20 April 2023, 18.47% of the Company's securities is not in public hands.
Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.
Restrictions in transfer of AIM securities
There are no restrictions on the transfer of the Company's ordinary shares.
UK City Code on Takeovers and Mergers
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Other exchanges and trading platforms
Fusion Antibodies has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
Page last updated: 14 August 2023